Compare CLGN & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLGN | CODX |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 15.6M |
| IPO Year | N/A | 2017 |
| Metric | CLGN | CODX |
|---|---|---|
| Price | $1.44 | $6.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $11.50 | ★ $67.50 |
| AVG Volume (30 Days) | 40.1K | ★ 78.6K |
| Earning Date | 11-26-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,475,000.00 | $507,892.00 |
| Revenue This Year | $1,596.12 | N/A |
| Revenue Next Year | $85.83 | $18.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 280.77 | N/A |
| 52 Week Low | $1.30 | $4.84 |
| 52 Week High | $4.98 | $46.50 |
| Indicator | CLGN | CODX |
|---|---|---|
| Relative Strength Index (RSI) | 37.10 | 96.23 |
| Support Level | $1.37 | $0.17 |
| Resistance Level | $1.51 | $0.30 |
| Average True Range (ATR) | 0.11 | 0.26 |
| MACD | 0.02 | 0.68 |
| Stochastic Oscillator | 53.78 | 97.08 |
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.